日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2

阿米万他单抗联合拉泽替尼治疗非典型 EGFR 突变型晚期非小细胞肺癌:CHRYSALIS-2 研究结果

Tomasini, Pascale; Wang, Yongsheng; Li, Yongsheng; Felip, Enriqueta; Wu, Lin; Cui, Jiuwei; Besse, Benjamin; Spira, Alexander I; Neal, Joel W; Goto, Koichi; Baik, Christina S; Marmarelis, Melina E; Ichihara, Eiki; Zhang, Yiping; Lee, Jong-Seok; Lee, Se-Hoon; Yang, James Chih-Hsin; Michels, Sebastian; Anastasiou, Zacharias; Curtin, Joshua C; Lyu, Xuesong; Mahoney, Janine; Demirdjian, Levon; Meyer, Craig S; Zhang, Youyi; Leconte, Isabelle; Lorenzini, Patricia; Knoblauch, Roland E; Trani, Leonardo; Baig, Mahadi; Bauml, Joshua M; Cho, Byoung Chul

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC

JIN-A02 是一种突变选择性第四代 EGFR 抑制剂,可克服 C797S 介导的耐药性,并在非小细胞肺癌中显示出颅内活性。

Lee, Eun Ji; Ko, Ji Ae; Kim, Min-Je; Cho, Jae Seok; Han, Ji-Youn; Kim, Sang We; Lee, Ki Hyeong; Shim, Byoung Yong; Sun, Jong-Mu; Nagasaka, Misako; Park, Sewon; Oh, Seung Yeon; Hong, Min Hee; Lee, Jii Bum; Jo, Anna; Seah, Ethan; Cho, Byoung Chul; Lim, Sun Min

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies

Fianlimab(一种人淋巴细胞活化基因-3单克隆抗体)联合cemiplimab:晚期恶性肿瘤的肿瘤特异性扩展队列研究

Kim, Tae Min; Williamson, Stephen K; Papadopoulos, Kyriakos P; Hamid, Omid; Dy, Grace K; McDermott, Ray; Birnbaum, Ariel; Kaczmar, John M; Lakhani, Nehal; Rischin, Danny; Sarker, Debashis; Dowlati, Afshin; Zhu, Xin-Hua; Malhotra, Jyoti; Pouliot, Jean-Francois; Mani, Jayakumar; Brennan, Laura; Fang, Fang; Chen, Shuquan; Salvati, Mark; Lowy, Israel; Khaled, Ahmed; Lewis, Karl D; Kroog, Glenn; Fury, Matthew G; Cho, Byoung Chul

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Durvalumab联合化疗治疗一线奥希替尼治疗后疾病进展的EGFR突变晚期非小细胞肺癌患者:ORCHARD

Cho, Byoung Chul; Nishio, Makoto; Ahn, Myung-Ju; García-Campelo, Rosario; Ponce, Santiago; Baik, Christina; Salgia, Ravi; Kim, Sang-We; Lee, Jong Seok; Yoshida, Tatsuya; Yu, Helena A; Goldberg, Sarah B; Johannes de Langen, Adrianus; Le, Xiuning; Piotrowska, Zofia; Riess, Jonathan W; Tanaka, Kentaro; Ambrose, Helen; Cosaert, Jan; Fraenkel, Paula G; Tang, Kwan Ho; Lehman, Jonathan M; Smith, Paul; Goldman, Jonathan W

Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes

基于组织病理学分期和EGFR分子亚型的EGFR突变型非小细胞肺癌(NSCLC)的分子和临床差异

Yoon, Dayoung; Lee, Ji Won; Cho, Byoung Chul; Kang, Eun Joo; Kim, Jung Sun; Lim, Taekyu; Yi, Seong Yoon; Kim, Yu Jung; Ahn, Mi Sun; Kim, Young Saing; Park, Ji Hyun; Lim, Seungtaek; Park, Hyung Soon; Cho, Jang Ho; Jang, Byunghyun; Lee, Ji Yoon; Kim, Jiwon; Hong, Jisoo; Koo, Harim; Chung, Seok; Shin, Sang Won; Kim, Yeul Hong; Sa, Jason K; Choi, Yoon Ji

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

达托泊单抗德鲁西替康治疗具有可靶向基因组改变的晚期或转移性非小细胞肺癌:来自 II 期 TROPION-Lung05 研究的结果

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George Jr; Shum, Elaine; Pons Tostivint, Elvire; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca; Shimizu, Junichi; Lee, Jong-Seok; Baas, Paul; Planchard, David; Pérol, Maurice; Felip, Enriqueta; Su, Wu-Chou; Zebger-Gong, Hong; Lan, Lan; Liu, Chelsea; Howarth, Paul; Chiaverelli, Rachel; Paz-Ares, Luis

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

在III期EXCLAIM-2试验中,一线Mobocertinib与铂类化疗在EGFR 20号外显子插入阳性转移性非小细胞肺癌患者中的疗效比较

Jänne, Pasi A; Wang, Bin-Chao; Cho, Byoung Chul; Zhao, Jun; Li, Juan; Hochmair, Maximilian; Peters, Solange; Besse, Benjamin; Pavlakis, Nick; Neal, Joel W; Kato, Terufumi; Wu, Yi-Long; Nguyen, Danny; Lin, Junjing; Lin, Jianchang; Vranceanu, Florin; Szumski, Annette; Lin, Huamao M; Fram, Robert J; Mok, Tony S K

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells

通过靶向耐药细胞的选择性优势来延长肺癌对 EGFR 抑制剂的反应时间

Brunet, Lisa; Alexandre, David; Lee, Jiyoung; Blanquer-Rosselló, Maria Del Mar; Bracquemond, David; Guernet, Alexis; Chhouri, Houssein; Goupil, Mathilde; Kherrouche, Zoulika; Arabo, Arnaud; Mancini, Maicol; Cartier, Dorthe; Yao, Shen; Godefroy, David; Dehedin, Julie; Li, Jian-Rong; Duparc, Céline; Jamme, Philippe; Vinchent, Audrey; Bérard, Caroline; Tulasne, David; Arena, Sabrina; Bardelli, Alberto; Cheng, Chao; Cho, Byoung Chul; Wurtz, Olivier; Coulouarn, Cédric; Maraver, Antonio; Aaronson, Stuart A; Cortot, Alexis B; Anouar, Youssef; Grumolato, Luca

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

在既往接受过免疫检查点抑制剂和化疗的转移性非小细胞肺癌患者中,阿特珠单抗联合贝伐珠单抗(无论是否联合放疗)与多西他赛相比的疗效:来自随机、Ib/II期MORPHEUS-Lung研究的结果

Ghiringhelli, Francois; Lawrence, Yaacov R; Felip, Enriqueta; Zer, Alona; Greillier, Laurent; Greystoke, Alastair; Pardo, Nuria; Al-Sakaff, Nedal; Helms, Hans-Joachim; Prizant, Hen; Pintoffl, Jan; Lim, Farah Louise; Lim, Sun Min; Cho, Byoung Chul

Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC

人群调整后的瑞波替尼在ROS1阳性非小细胞肺癌患者中的间接治疗比较

Wolf, Jürgen; Goring, Sarah; Lee, Adam; Cho, Byoung Chul; Drilon, Alexander; Yuan, Yong; Ayers, Dieter; Lozano-Ortega, Greta; Korol, Ellen E; Korpach, Sarah G; Crabtree, Madeleine; Huria, Lavanya; Calvet, Christophe Y; Camidge, D Ross